SocialPicks Sentiment:
** v.s.
other stocks
|
This Quarter's Sentiment:
|
|
|
ONXX Analysis & Videos »
ONXX: Bull or Bear?
Trading FDA, Clinical Trial Binary Events:$ONXX $BIO $ARNA
ONXX
|
|
|
+103.86%
in
680 days
Below are some Regulatory Catalyst Index updates for companies with recent FDA and clinical trial related news.... <> <font> Onyx Pharma (NASDAQ:ONXX) announced positive results from a single-agent Phase 2b study of carfilzomib (a selective, next-generation proteasome inhibitor anti-cancer agent) for relapsed / refractory multiple myeloma (MM) with 24% overall response rate and mediation duration of 7.4 months. ONXX expects to file a New Drug Application (NDA) by year-end 2010 for accelerated approval, in addition to its ongoing pivotal Phase 3 (US) combo ASPIRE study and a pending pivotal...
|
FDA Calendar Updates: BVX, HEB, HGSI, ONXX, SGP
ONXX
|
|
|
-38.08%
in
369 days
(closed on 07/26/10)
<> Below is a summary of updates to the <font> BioMedReports.com FDA Calendar </font> , which includes a database of 273 entries as of 7/22/09. The calendar was originally created by Mike Havrilla to track companies with pending new drug, biological agent, or medical device new product decisions at the FDA. With the launch of <font> BioMedReports.com </font> , the FDA Calendar has expanded to include the following categories: pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), pending complete response letter (CRL) re-submissions to the FDA, and pendin...
|
Who's Next in the Biotech Buyout Frenzy?
ONXX
|
|
|
+20.30%
in
281 days
(closed on 07/22/09)
<> The biotech industry is rapidly consolidating as big pharma companies put their cash stash to use in deals ranging from well-known large caps all the way down to unknown micro-caps in an effort to bolster their range of marketed products, late stage pipeline candidates, and drug discovery technology platforms.
Genentech (DNA) has rejected Roche's (RHHBY) $89 bid to acquire the remaining 44% of DNA it does not already own as insufficient. I think DNA could easily get $100 per share based on Eli Lilly's (LLY) $70 buyout of ImClo...
|
Upgrading Onyx Pharma to Buy
ONXX
+19.82%
in
1489 days
We believe Nexavar sales will continue to grow over the next several years since the label has expanded to liver cancer.
|
Not selling yet...
ONXX
|
|
|
+266.78%
in
2000 days
I played my cards right and bought as the stock dropped after Nexavar failed to be approved for the treatment of melanoma. I was already looking toward the possible approval of uses for other cancers such as liver.
ONYX may pull back into the low 20's over the next few months, but with the buyout possibilities and more firms watching this company (and buying) I am going to ride out those small bumps. If it drops below 22 I'll be buying more.
|
People Bullish on ONXX
People Bearish on ONXX
|
ROCK-STAR INVESTORS
|
|
POPULAR STOCKS
|
|
TODAY'S HEADLINES
|
|
TODAY'S TOP PICKS
|
|
|
| StreetInsider.com on ONXX |
More Resources
|
About ONYX Pharmaceuticals Inc.
- Answers.com
